Thread Four

Advancing Worsening Heart Failure Treatment: Exploring Cutting-Edge Therapies and Addressing Disparities

Faculty

Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

Director of Mount Sinai Heart
Dr. Valentin Fuster Professor of Cardiovascular Medicine
Icahn School of Medicine at Mount Sinai
New York, NY

Erin Michos, MD, MHS

Director of Women Cardiovascular Health Research

Associate Director of Preventive Cardiology at Johns Hopkins University School of Medicine
Co-Director, IMPACT Center at Johns Hopkins University
Co-Editor in Chief, American Journal of Preventive Cardiology
Baltimore, MD



Program Overview

HFrEF is a progressive and complex condition with very high rates of mortality and hospitalizations. Recently, positive cardiovascular (CV) outcomes and reduced hospitalization for heart failure (HF) were noted in patients with HF with reduced ejection fraction (HFrEF) treated with novel emerging agents. The inclusion of the soluble guanylate cyclase (sGC) stimulator, vericiguat; and the sodium-glucose cotransporter-2 (SGLT2), empagliflozin and dapagliflozin; have revolutionized the treatment of patients with HFrEF. The treatment of HFrEF requires one or more drugs from several classes, as recommended in the guidelines. Many factors need to be considered when selecting therapy for these patients, including how to initiate, add, or switch therapies, and how to assess the effectiveness of these treatments using imaging and biomarkers. Recent additions to guidelines including SGLT2 inhibitors and vericiguat have the potential to significantly decrease risk for hospitalization for patients with HFrEF. Timely implementation of these therapies is critical to achieve the anticipated health benefits.

Target Audience

This educational initiative is designed for cardiologists, preventive cardiologists, emergency department (ED) physicians, and all clinicians interested in managing patients with heart failure.

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Discuss health disparities in the diagnosis and treatment of HF and strategies to reduce these disparities

Accreditation

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Iridium. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must
  • Read the learning objectives and faculty disclosures Complete the pretest
  • View the enduring material
  • Complete the posttest with a score of 70% or higher


A statement of credit will be issued within four weeks of receipt of a completed activity evaluation form.

System Requirements

PC
1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)
Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)

MAC
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14
Mozilla Firefox, Apple Safari, Google Chrome
For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Fee Information and Refund/Cancellation Policy

There is no fee for this educational activity.

Term Offering

This activity was released on 2/15/2024 and is valid for one year. Requests for credit must be made no later than 2/15/2025.

Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected]

Disclosures

Disclosures of Relevant Financial Relationships

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:


Deepak Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI
Consulting Fee (e.g., Advisory Board): Angiowave, Bayer, Boehringer Ingelheim, Broadview Ventures, CellProthera, Cereno Scientific, Hims, Janssen, McKinsey, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, SFJ, Stasys, Youngene
Contracted Research (Principal Investigators must provide information, even if received by the institution): Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Biotronik, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, CSI, Eisai, Endotronix, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, Philips, PLx Pharma, Recardio, Regeneron, Roche, Sanofi, SpectraWAVE, Stasys, St. Jude Medical (Abbott), Svelte, The Medicines Company, Youngene, Vascular Solutions, 89Bio
Honoraria: CSL Behring, MJH Life Sciences
Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Bristol Myers Squibb
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Angiowave, DRS.LINQ
Other: Board of Directors: Angiowave, Bristol Myers Squibb, DRS.LINQ                
Data Monitoring Committees: Acesion Pharma, Boston Scientific, Novartis Patent: Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon)

Erin Michos, MD, MHS

Consulting Fee (e.g., Advisory Board):
Amgen, AstraZeneca, Boehringer Ingelheim, Edwards Lifescience, Esperion, Medtronic, Merck, Novartis, Novo Nordisk, New Amsterdam, Pfizer

The following planners and managers involved in the development of this activity have no relevant financial relationships with ineligible companies to disclose.

Global
The planners and managers at Global Education Group have no relevant financial relationships to disclose.

Iridium
Iridium staff and others involved with the planning, development, and review of the content for this activity have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Iridium do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is jointly provided by Global Education Group and Iridium Continuing Education.
SUPPORTER ACKNOWLEDGEMENT
This activity is supported by an independent educational grant from
Merck, Sharpe, and Dohme, LLC.